Topline results from a phase 2/3 clinical trial showed that an eIF2B agonist to treat ALS failed to meet its primary endpoint of slowing disease progression compared with placebo at week 24.According ...
DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.
For the primary analysis, a total of 186 participants who received DNL343 treatment were compared to 139 participants who ...
In her husband's nearly 15 years of living with ALS, columnist Kristin Neva sees pre- and post-diagnosis papers as a bittersweet treasure.
Fast-growing wildfires raging in Los Angeles killed at least two people on Wednesday, destroying hundreds of buildings, scorching hillsides and prompting officials to order some 70,000 people to ...
That's all for our live coverage of the war in Ukraine. We'll be back tomorrow with more updates. Here's a rundown of the key lines from today: Ukraine's military has said it was responsible for a ...
DHAKA: Ailing former Bangladesh PM and BNP chief Khaleda Zia on Wednesday met her son Tarique Rahman in London after more than seven years, a reunion made possible by a changed political scenario ...
Copyright 2025 The Associated Press. All Rights Reserved. Remote, icy and mostly pristine, Greenland plays an outsized role in the daily weather experienced by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback